New registry to monitor growth hormone treatment in kids with rare condition
NCT ID NCT05308927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on growth, side effects, and quality of life over time. No new treatment is being tested—the goal is to learn more about how this approved medicine works in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOONAN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ap-Hp-Hopital de Bicetre-2
Le Kremlin-Bicêtre, 94275, France
-
Centre Hospitalier Universitaire D'Angers-2
Angers, 49033, France
-
Hopital Des Enfants-2
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Noonan syndrome study aims to uncover hidden heart risks
- Noonan syndrome research: scientists launch sample collection to unlock disease secrets
- New drug aims to boost growth in kids with noonan syndrome
- New program aims to ease burden on families of kids with rare diseases
- New study tests online therapy to ease stress for parents of kids with RASopathies
- New scan techniques aim to solve rare heart disease mysteries